Gopal Krishana Bohra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gopal Krishana Bohra has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Durga Shankar Meena
Division of Infectious Diseases, Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, India
13 shared publications - Deepak Kumar
Department of Medicine and Infectious Diseases, All India Institute of Medical Science , Jodhpur, Rajasthan
11 shared publications - Mahendra Kumar Garg
Department of General Medicine, All India Institute of Medical Sciences, Jodhpur, India
9 shared publications - Naresh Kumar Midha
Department of General Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, India
7 shared publications Deepak Kumar
MD, Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, India
4 shared publications- Pawan Kumar Garg
Department of Diagnostic and Interventional Radiology, All India Institute of Medical Sciences, Jodhpur, India
4 shared publications
Latest Publications
- 15 October 2026
- Published by Springer Nature in Infection
- p. 1-10
Serum hepcidin as a host-derived biomarker of disease severity and risk stratification in tuberculosis
- 15 October 2026
- Published by Springer Nature in Infection
- p. 1-10
Serum hepcidin as a host-derived biomarker of disease severity and risk stratification in tuberculosis
- Open Access
- 24 September 2026
- Published by Scientific Scholar in Journal of Hematology and Allied Sciences
- p. 1-4
True non-secretory multiple myeloma in a resource-limited setting: A diagnostic challenge
True non-secretory multiple myeloma (NSMM), defined by absent monoclonal protein on serum/urine electrophoresis, immunofixation, and free light-chain assay, accounts for <1% of myeloma cases. We report a 49-year-old male with recurrent fever and bone pain in whom all serologic markers were negative; a weakly positive anti-Ro antibody initially suggested autoimmune disease. Fluorodeoxyglucose positron emission tomography computed tomography (PET-CT) revealed diffuse hypermetabolic axial marrow involvement, and bone marrow biopsy confirmed 12% clonal plasma cells cluster of differentiation ([CD]38/CD138/CD56-positive), establishing International Staging System stage II NSMM. Bortezomib-lenalidomide-dexamethasone achieved minimal residual disease (MRD)-negative stringent complete response with complete metabolic response by PET-CT and multiparametric flow cytometry after four cycles. He remains on lenalidomide maintenance at 12 months. Negative electrophoresis does not exclude myeloma; PET-CT and marrow-based MRD assessment are indispensable in NSMM.
- 24 September 2026
- Published by Scientific Scholar in Journal of Hematology and Allied Sciences
- p. 1-4
Open AccessTrue non-secretory multiple myeloma in a resource-limited setting: A diagnostic challenge
True non-secretory multiple myeloma (NSMM), defined by absent monoclonal protein on serum/urine electrophoresis, immunofixation, and free light-chain assay, accounts for <1% of myeloma cases. We report a 49-year-old male with recurrent fever and bone pain in whom all serologic markers were negative; a weakly positive anti-Ro antibody initially suggested autoimmune disease. Fluorodeoxyglucose positron emission tomography computed tomography (PET-CT) revealed diffuse hypermetabolic axial marrow involvement, and bone marrow biopsy confirmed 12% clonal plasma cells cluster of differentiation ([CD]38/CD138/CD56-positive), establishing International Staging System stage II NSMM. Bortezomib-lenalidomide-dexamethasone achieved minimal residual disease (MRD)-negative stringent complete response with complete metabolic response by PET-CT and multiparametric flow cytometry after four cycles. He remains on lenalidomide maintenance at 12 months. Negative electrophoresis does not exclude myeloma; PET-CT and marrow-based MRD assessment are indispensable in NSMM.
- Open Access
- 12 August 2026
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Persistent Staphylococcus aureus bacteremia and 30-day mortality: a systematic review and meta-analysis
- 12 August 2026
- Published by Springer Nature in Systematic Reviews
- Vol. 15 (1)
Open AccessPersistent Staphylococcus aureus bacteremia and 30-day mortality: a systematic review and meta-analysis
- Open Access
- 24 March 2026
- Published by Elsevier in Indian Heart Journal
- Vol. 78 (5) , 232-237
Revisiting Non-HACEK Gram-Negative Endocarditis: Emerging Clinical and Microbiological Trends from a Prospective Cohort
- 24 March 2026
- Published by Elsevier in Indian Heart Journal
- Vol. 78 (5) , 232-237
Open AccessRevisiting Non-HACEK Gram-Negative Endocarditis: Emerging Clinical and Microbiological Trends from a Prospective Cohort
- Open Access
- 26 January 2026
- Published by Springer Nature in Journal of Rare Diseases
- Vol. 5 (1) , 10
Acute intermittent porphyria in a resource-limited setting: diagnostic pitfalls and emerging therapeutic perspectives
Background: Acute intermittent porphyria (AIP) is a rare metabolic disorder caused by deficiency of hydroxymethylbilane synthase (HMBS), leading to accumulation of neurotoxic heme precursors. Its protean neurovisceral manifestations and the possibility of false-negative biochemical assays make diagnosis challenging, particularly in low- and middle-income countries (LMICs), where access to specialized diagnostics and definitive therapy is often limited. Case Summary: We report a 32-year-old woman with recurrent episodes of abdominal pain, vomiting, hyponatremia, episodic hypertension, and neurological deficits who underwent extensive evaluation at multiple centers without a unifying diagnosis. Despite repeated negative qualitative urinary porphobilinogen (PBG) assays, strong clinical suspicion was maintained, supported by bedside observation of progressive urine darkening on light exposure. Repeat testing during an acute symptomatic phase confirmed elevated urinary PBG and δ-aminolevulinic acid (ALA) levels, and genetic analysis identified a pathogenic HMBS mutation (c.77G>A; p.Arg26His), establishing the diagnosis of AIP. The patient was managed with high-carbohydrate supplementation and supportive care, as intravenous hemin was unavailable. Discussion: This case illustrates common diagnostic pitfalls in AIP, including overreliance on negative qualitative screening tests, fragmented symptom-based management, and limited access to quantitative assays in resource-constrained settings. Recent advances, including standardized biochemical testing, confirmatory genetic analysis, and disease-modifying therapy with givosiran, have transformed AIP management in high-income countries; however, their limited availability in LMICs continues to result in diagnostic delay and therapeutic inequity.
- 26 January 2026
- Published by Springer Nature in Journal of Rare Diseases
- Vol. 5 (1) , 10
Open AccessAcute intermittent porphyria in a resource-limited setting: diagnostic pitfalls and emerging therapeutic perspectives
Background: Acute intermittent porphyria (AIP) is a rare metabolic disorder caused by deficiency of hydroxymethylbilane synthase (HMBS), leading to accumulation of neurotoxic heme precursors. Its protean neurovisceral manifestations and the possibility of false-negative biochemical assays make diagnosis challenging, particularly in low- and middle-income countries (LMICs), where access to specialized diagnostics and definitive therapy is often limited. Case Summary: We report a 32-year-old woman with recurrent episodes of abdominal pain, vomiting, hyponatremia, episodic hypertension, and neurological deficits who underwent extensive evaluation at multiple centers without a unifying diagnosis. Despite repeated negative qualitative urinary porphobilinogen (PBG) assays, strong clinical suspicion was maintained, supported by bedside observation of progressive urine darkening on light exposure. Repeat testing during an acute symptomatic phase confirmed elevated urinary PBG and δ-aminolevulinic acid (ALA) levels, and genetic analysis identified a pathogenic HMBS mutation (c.77G>A; p.Arg26His), establishing the diagnosis of AIP. The patient was managed with high-carbohydrate supplementation and supportive care, as intravenous hemin was unavailable. Discussion: This case illustrates common diagnostic pitfalls in AIP, including overreliance on negative qualitative screening tests, fragmented symptom-based management, and limited access to quantitative assays in resource-constrained settings. Recent advances, including standardized biochemical testing, confirmatory genetic analysis, and disease-modifying therapy with givosiran, have transformed AIP management in high-income countries; however, their limited availability in LMICs continues to result in diagnostic delay and therapeutic inequity.
- Open Access
- 3 November 2025
- Published by Springer Nature in International Journal of Emergency Medicine
- Vol. 18 (1) , 1-6
When methylene blue fails: a case of methemoglobinemia induced by azoxystrobin and propiconazole managed by exchange transfusion
Methemoglobinemia is a potentially life-threatening condition resulting from the oxidation of hemoglobin’s iron moiety from ferrous (Fe²⁺) to ferric (Fe³⁺). Clinical features include cyanosis unresponsive to oxygen therapy, chocolate-colored blood, and a marked saturation gap between pulse oximetry and arterial blood gas. Methylene blue remains the cornerstone of treatment; however, in rare instances, patients may exhibit refractory responses necessitating advanced interventions. Literature documenting methemoglobinemia due to fungicides like azoxystrobin and propiconazole remains scarce. A young female presented with altered sensorium, shock, and hypoxia following the ingestion of a fungicide containing azoxystrobin and propiconazole. Despite a PaO₂ of 400 mmHg on ABG, pulse oximetry showed 83% oxygen saturation, raising suspicion of dyshemoglobinemia. Methemoglobin levels were elevated at 80.7%. She was treated with intravenous methylene blue. While an initial decline in methemoglobin levels to 4% was observed, relapse occurred within 12 h. On day three, therapeutic red blood cell exchange transfusion was performed resulting in a reduction of methemoglobin levels to 14.2%. Despite aggressive measures, she succumbed to refractory shock on day five of admission. This report presents likely the first documented case of fatal methemoglobinemia due to ingestion of azoxystrobin and propiconazole—a combination fungicide widely used in agriculture. The case highlights the limitations of standard therapies like methylene blue in severe poisoning and underscores the need for early consideration of exchange transfusion. With the increasing use of such agents in rural communities, clinicians must maintain vigilance for unusual toxicities and ensure timely escalation in refractory cases.
- 3 November 2025
- Published by Springer Nature in International Journal of Emergency Medicine
- Vol. 18 (1) , 1-6
Open AccessWhen methylene blue fails: a case of methemoglobinemia induced by azoxystrobin and propiconazole managed by exchange transfusion
Methemoglobinemia is a potentially life-threatening condition resulting from the oxidation of hemoglobin’s iron moiety from ferrous (Fe²⁺) to ferric (Fe³⁺). Clinical features include cyanosis unresponsive to oxygen therapy, chocolate-colored blood, and a marked saturation gap between pulse oximetry and arterial blood gas. Methylene blue remains the cornerstone of treatment; however, in rare instances, patients may exhibit refractory responses necessitating advanced interventions. Literature documenting methemoglobinemia due to fungicides like azoxystrobin and propiconazole remains scarce. A young female presented with altered sensorium, shock, and hypoxia following the ingestion of a fungicide containing azoxystrobin and propiconazole. Despite a PaO₂ of 400 mmHg on ABG, pulse oximetry showed 83% oxygen saturation, raising suspicion of dyshemoglobinemia. Methemoglobin levels were elevated at 80.7%. She was treated with intravenous methylene blue. While an initial decline in methemoglobin levels to 4% was observed, relapse occurred within 12 h. On day three, therapeutic red blood cell exchange transfusion was performed resulting in a reduction of methemoglobin levels to 14.2%. Despite aggressive measures, she succumbed to refractory shock on day five of admission. This report presents likely the first documented case of fatal methemoglobinemia due to ingestion of azoxystrobin and propiconazole—a combination fungicide widely used in agriculture. The case highlights the limitations of standard therapies like methylene blue in severe poisoning and underscores the need for early consideration of exchange transfusion. With the increasing use of such agents in rural communities, clinicians must maintain vigilance for unusual toxicities and ensure timely escalation in refractory cases.
- 28 August 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 1032-1036
Expression of Anti-parietal Cell Antibody (APCA) and Intrinsic Factor Blocking Antibody (IFBA) in Individuals with Vitamin B12 Deficiency: Experience from a Tertiary Care Centre from India
Vitamin B12 deficiency is a worldwide public health issue, with its prevalence high in the developing countries. It is a micronutrient synthesized by microorganisms and obtained through diet and its deficiency can lead to megaloblastic anaemia and neurological deficits. The elderly are more prone to it. Pernicious anaemia is a prevalent cause of megaloblastic anaemia, which is associated with autoimmune destruction of parietal cells and intrinsic factor deficiency by APCA and AIFA antibodies. These antibodies can cause mucosal damage and hinder vitamin B12 absorption. The present prospective observational study included 166 patients with severe vitamin B12 deficiency (defined by Vitamin B12 levels ≤ 150 pg/mL) who were treated at a tertiary care centre in western Rajasthan. Expression of AIFA and APCA were assessed and their association with different parameters were evaluated. The present study didnot find any significant association between APCA and AIFA impressions, indicating that the absence or presence of one antibody did not strongly predict the presence or absence of the other antibody. This suggests that these autoantibodies may have distinct roles or mechanisms in PA and further research is needed to understand their relationship.
- 28 August 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 1032-1036
Expression of Anti-parietal Cell Antibody (APCA) and Intrinsic Factor Blocking Antibody (IFBA) in Individuals with Vitamin B12 Deficiency: Experience from a Tertiary Care Centre from India
Vitamin B12 deficiency is a worldwide public health issue, with its prevalence high in the developing countries. It is a micronutrient synthesized by microorganisms and obtained through diet and its deficiency can lead to megaloblastic anaemia and neurological deficits. The elderly are more prone to it. Pernicious anaemia is a prevalent cause of megaloblastic anaemia, which is associated with autoimmune destruction of parietal cells and intrinsic factor deficiency by APCA and AIFA antibodies. These antibodies can cause mucosal damage and hinder vitamin B12 absorption. The present prospective observational study included 166 patients with severe vitamin B12 deficiency (defined by Vitamin B12 levels ≤ 150 pg/mL) who were treated at a tertiary care centre in western Rajasthan. Expression of AIFA and APCA were assessed and their association with different parameters were evaluated. The present study didnot find any significant association between APCA and AIFA impressions, indicating that the absence or presence of one antibody did not strongly predict the presence or absence of the other antibody. This suggests that these autoantibodies may have distinct roles or mechanisms in PA and further research is needed to understand their relationship.